why choose us

First received: August 25, 2023

Clinical Trial: A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Classical Hodgkin Lymphoma

Study Type: INTERVENTIONAL


Official Title: A Phase 1/2a, Open-Label, Dose Escalation Trial of GEN3017 With Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma

Brief Summary: The purpose of this trial is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of GEN3017 as a monotherapy in participants with relapsed or refractory (R/R) CD30-expressing lymphomas.GEN3017 will be administered via subcutaneous injections.All participants will receive active drug; no one will be given placebo.

Read more